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1 |  INTRODUCTION
Intimal sarcoma of the pulmonary artery is a rare tumor with 
poor oncological outcomes. We report here the case of a 
patient with 4 years long‐term survival after treatment with 
surgery, chemotherapy, and radiotherapy with good local 
control. This case highlights the possible role of radiation 
therapy in this tumor.
Primary pulmonary artery sarcomas (PAS) are the most fre-
quent sarcoma of the great arteries. Most PAS are derived from 
the embryologic bulbus cordis area, mainly from the pulmo-
nary artery. Intimal sarcoma of the pulmonary artery (PAIS) 
is a rare tumor with an estimated incidence between 0.001% 
and 0.003%,1 which is likely an underestimate due to frequent 
misdiagnosis and late detection during surgery or autopsy.2 
Median overall survival (OS) of approximately 17 months is 
reported in the literature for PAIS patients.3 Surgery remains 
the mainstay of management for patients with PAIS, even 
though the use of various chemotherapy agents has been re-
ported.3,4 To date, the role of radiotherapy remains unclear.5
Below, we report the case of a woman with long‐term 
survival from PAIS who was initially treated with surgical 
resection and postoperative chemotherapy, which was suc-
cessfully treated with repeated (fractionated) courses of 
radiotherapy.
2 |  CASE REPORT
The patient, a 62‐year‐old woman, reported a history of 
pulmonary hypertension since March 2010 with findings 
of a high D‐dimer, shortness of breath, and chest pain. In 
April 2014, during follow‐up for her pulmonary hyperten-
sion, chest computed tomography (CT) revealed the pres-
ence of a solid mass originating from the main pulmonary 
artery with a maximal extension of 37 mm and involvement 
of the pulmonary valve but without signs of extravascular 
invasion. The subsequent 18‐fluorodeoxyglucose positron 
emission tomography (18 FDG PET/CT) confirmed chest 
CT findings with pathologic uptake at the pulmonary trunk. 
In May 2014, she underwent pulmonary endarterectomy 
(PEA) and paratracheal lymphadenectomy. The defini-
tive histological diagnosis was poorly differentiated mes-
enchymal tumor with strong fibroblastic differentiation at 
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immunohistochemistry, consistent with pulmonary arterial 
intimal sarcoma (KI67 30%, G3, mitotic index >20, necro-
sis <50%); negative nodes (0/6) but positive margins (right 
and left margin of pulmonary artery and the margin of ven-
tricular). Due to the negative CT re‐evaluation 1  month 
after surgery, the patient received four cycles of adjuvant 
chemotherapy combining adriamycin and ifosfamide be-
tween June and September 2014. The forth chemotherapy 
cycle was complicated by neurological toxicity and a diag-
nosis of encephalopathy, which resolved completely. From 
October to December 2014, the patient underwent adjuvant 
radiation treatment, which was delivered by Hi‐Art helical 
tomotherapy and daily image guided radiotherapy (IGRT). 
A CT simulation scan with 2.5  mm slices was acquired, 
and the following volumes were identified: clinical target 
volume (CTV), including the surgical areas of pulmonary 
artery; planning target volume (PTV), defined adding 5 mm 
to CTV; organs at risk (OARs), such as spinal cord, esopha-
gus, heart, and right and left lungs. The prescribed dose was 
60  Gy in 30 fractions, five fractions per week (Figure 1). 
The radiotherapy treatment was well tolerated with no rel-
evant toxicity. At the end of the radiotherapy, the patient 
started a regular clinical and radiological follow‐up. In May 
2016, 19 months after external beam radiotherapy (EBRT), 
a chest CT revealed a solid nodule of 7  ×  6  mm located 
nearby the inferior wall of the pulmonary artery descend-
ing branch. The lesion was suspicious for recurrence, but 
was too small to be defined. Close radiological follow‐up 
with repeated chest CTs in July 2016, October 2016, and 
January 2017 revealed stability in nodule size. In July 2017, 
the CT scan revealed a pulmonary descending artery fill-
ing defect; however, the defect increased in size three times 
compared to its original size. No evidence of distant me-
tastases was observed. From September to November 2017, 
the patient underwent second‐line chemotherapy (Docetaxel 
and Gemcitabina—4 cycles). This regimen was interrupted 
because of disease progression at CT re‐evaluation (lesion 
of 30 mm in maximum size that involved the whole lumen 
of the inferior right pulmonary artery). Particle radiations 
treatment was evaluated at Protontherapy Center, Pavia, but 
the site of the lesion was not compatible and photon reir-
radiation concomitant to pazopanib was proposed. This 
second radiotherapy treatment (reRT) was delivered in 
February 2018 by VMAT technique with LINAC (VARIAN 
Trilogy). The re‐RT dose prescribed was 24 Gy in 4 frac-
tions, once a week, with energy of 6 MV. The CTV included 
F I G U R E  1  Dose distribution of 
helical tomotherapy plan
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the macroscopic disease plus a 5  mm margin (Figure 2). 
Like the first one, this EBRT treatment was well tolerated. 
An early CT performed 1 month after reRT revealed a par-
tial response with maximum lesion size reduction from 3 to 
2 cm. In June 2018, a further CT scan showed stable disease. 
In view of the lack of change and reasonable tolerability, the 
patient will continue Pazopanib treatment.
3 |  DISCUSSION
Primary pulmonary artery sarcomas (PAS) are the most fre-
quent sarcomas of the great arteries characterized by local 
growth, with only a slight ability to metastasize.2 They typi-
cally affect middle‐aged people, particularly women, with a 
mean age at diagnosis of 48 years.2 Our patient had an older 
age of onset than is generally reported in literature. The aim 
of this paper is to report our experiences with a patient who 
had long‐term (50  month) survival with PAS, considering 
that this disease has a poor prognosis and a median OS of 
17 months.3 Diagnosis of PAS is difficult and often delayed 
due to the nonspecific nature of the symptoms. It is often 
confused with pulmonary thromboembolism and is therefore 
treated inappropriately with prolonged anticoagulation or 
thrombolysis.6 Common symptoms at the time of presenta-
tion are progressive dyspnea, cough, chest pain, and weight 
loss. The patient described here presented with all the above 
symptoms but had been diagnosed with pulmonary hyper-
tension 4 years prior. This misdiagnosis is quite common as 
PAS starts with nonspecific symptoms and it can be easily 
confused with pulmonary embolism; however, the onset of 
the symptoms is usually more gradual with PAS than pulmo-
nary embolism.1 In our patient, this missed diagnosis led to a 
delay in therapy that could have affected outcomes. Surgical 
treatment remains the mainstay of management for patients 
with PAIS and can include pulmonary endarterectomy, lobec-
tomy, or pneumonectomy depending on mono or bilateral 
disease.7 The correct surgical approach must be evaluated 
individually, according to the tumor presentation, the pres-
ence of pulmonary hypertension, and the patient's clinical 
condition.8 Surgery can prolong survival and often improve 
symptoms but margin status, like in this case, is rarely clear. 
For this reason, the patient underwent adjuvant treatment.3 
Chemotherapy is normally given postoperatively, although 
cases of improved outcome with neoadjuvant chemotherapy 
have been described. It is not clear if adjuvant chemo and 
F I G U R E  2  VARIAN Trilogy dose 
distribution
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radiotherapy bring any improvement, but some data reported 
an increased OS in patients who received multimodality 
therapy vs patients who received one single therapy9 and 
our patient received both chemo and radiotherapy. Several 
perioperative agents have been reported in the literature, 
including anthracyclines, ifosfamide, gemcitabine, taxanes, 
platinums, and immunotherapy. Anthracyclines, either alone 
or in combination, are the most commonly used agents. In 
our case, first‐line chemotherapy was adriamycin and ifos-
famide.3,4 The role of postoperative radiotherapy remains 
unclear.5 Chemotherapy regimens are normally followed by 
intensity modulated RT (IMRT) at a radical dose of 60 Gy 
in 30 fractions to surgical bed as happened in our patient.10 
Helical tomotherapy allows the delivery of higher doses to 
target volumes along with better sparing of normal tissues 
and to perform daily IGRT permitting us to correct any possi-
ble setup errors at every application, increasing the precision 
of the treatment and reducing interfraction changes.11 In our 
case, the patient had a disease‐free survival and was symp-
tom‐free for 19‐months after first EBRT. At recurrence, the 
patient was clearly refractory to the second chemotherapy 
therapeutic regimens and presented with disease progression. 
For this reason, a second RT course concomitant to new tar-
geted therapy was proposed. This re‐RT was delivered with 
a weekly fractionation in order to exploit a radiobiological 
rationale designed to increase the therapeutic index.12 The 
only targeted agent approved for use in soft tissue sarcoma 
at present is the tyrosine kinase inhibitor pazopanib, based 
on the results of the PALETTE trial.13 Pazopanib should be 
considered in patients with intimal sarcoma of the pulmo-
nary artery that is unresectable or recurrent after surgery or 
cytotoxic chemotherapy.14 This case suggests that the com-
bination of RT and pazopanib is safe and well tolerated and 
that disease recurrence may well respond precociously (re‐
evaluation after 1 month) and effectively to RT.
4 |  CONCLUSION
In this case, we can confirm the beneficial role of postopera-
tive radiotherapy and the safety of reirradiation on residual re-
currence. Early diagnosis could be an essential prerequisite to 
optimal management of PAS, especially by a multidisciplinary 
team. Being a rare and radioresistant cancer, more studies are 
still necessary to better understand the role of adjuvant treat-
ment and the role and timing of RT, which, as this case sug-
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